title: Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
authors.affiliation: Institute of Cancer Policy, King's College London, UK.
authors.forename: B
authors.initials: B
authors.lastname: Gyawali
authors.affiliation: Biomechanics Laboratory, Department of Mechanical Science and Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ando
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000601:surgery*; D058990:Molecular Targeted Therapy; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib